

Interstitial Cystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/I8AA8E8EEDFBEN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: I8AA8E8EEDFBEN

Abstracts

The 7 major interstitial cystitis markets reached a value of US\$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 5.07% during 2024-2034.

The interstitial cystitis market has been comprehensively analyzed in IMARC's new report titled "Interstitial Cystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Interstitial cystitis, also referred to as painful bladder syndrome, is a chronic condition that causes pressure and pain in the pelvis or bladder. Women are more likely to develop the disease than men, and the condition can occur at any age. Interstitial cystitis is characterized by chronic pelvic pain, pain during intercourse, discomfort while the bladder fills, an urgent desire to urinate, and relief after urinating. The bladder or pelvic discomfort ranges from mild to severe among patients. Individuals suffering from interstitial cystitis may also experience interrupted sleep, resulting in depression and lower quality of life. The diagnosis of this condition is based on a combination of medical history, physical exam, and diagnostic tests. The doctor may perform a urine culture to rule out a urinary tract infection and conduct a cystoscopy to examine the bladder lining. In addition to this, the doctor may also recommend urodynamics testing to evaluate bladder function and capacity. IC is often a diagnosis of exclusion, meaning that other conditions with similar symptoms must be ruled out first.

The rising incidences of bladder damage or injury and chronic inflammation in the bladder lining are primarily driving the interstitial cystitis market. Moreover, the increasing prevalence of several associated risk factors, such as neurogenic inflammation, pelvic floor dysfunction, autoimmune disorders, etc., is positively

influencing the market. In addition to this, the emerging popularity of microbiome-based therapies for alleviating indications, including pain, urinary frequency, urgency, etc., is also propelling the market growth. Furthermore, the escalating application of transcutaneous electrical nerve stimulation (TENS), since it aids in relieving symptoms by blocking the transmission of pain signals from the bladder to the brain and modulating nerve activity, is creating a positive outlook for the market. Apart from this, numerous key players are extensively focusing on the advancements of innovative treatments, such as gene and regenerative therapies, that have lesser side effects than conventional drugs. This, in turn, is also bolstering the market growth. Furthermore, the increasing utilization of sacral nerve stimulation implants for regulating bladder function and reducing the symptoms of the disease, including urinary urgency and frequency, in patients who have not responded to other treatments is expected to drive the interstitial cystitis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the interstitial cystitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for interstitial cystitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the interstitial cystitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the interstitial cystitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the interstitial cystitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current interstitial cystitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the interstitial cystitis market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the interstitial cystitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the interstitial cystitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of interstitial cystitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of interstitial cystitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of interstitial cystitis by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of interstitial cystitis by type across the seven major markets?

How many patients are diagnosed (2018-2034) with interstitial cystitis across the seven major markets?

What is the size of the interstitial cystitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of interstitial cystitis?

What will be the growth rate of patients across the seven major markets?

Interstitial Cystitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for interstitial cystitis drugs across the seven

major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the interstitial cystitis market?

What are the key regulatory events related to the interstitial cystitis market?

What is the structure of clinical trial landscape by status related to the interstitial cystitis market?

What is the structure of clinical trial landscape by phase related to the interstitial cystitis market?

What is the structure of clinical trial landscape by route of administration related to the interstitial cystitis market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTERSTITIAL CYSTITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 INTERSTITIAL CYSTITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 INTERSTITIAL CYSTITIS - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 INTERSTITIAL CYSTITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 INTERSTITIAL CYSTITIS - UNMET NEEDS

10 INTERSTITIAL CYSTITIS - KEY ENDPOINTS OF TREATMENT

11 INTERSTITIAL CYSTITIS - MARKETED PRODUCTS

- 11.1 List of Interstitial Cystitis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Elmiron (Pentosan polysulfate sodium) - Bene-Arzneimittel/ReqMed
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 INTERSTITIAL CYSTITIS - PIPELINE DRUGS

12.1 List of Interstitial Cystitis Pipeline Drugs Across the Top 7 Markets

12.1.1 Botox - AbbVie

12.1.1.1 Drug Overview

12.1.1.2 Mechanism of Action

12.1.1.3 Clinical Trial Results

12.1.1.4 Safety and Efficacy

12.1.1.5 Regulatory Status

12.1.2 SI722 - Seikagaku Corporation

12.1.2.1 Drug Overview

12.1.2.2 Mechanism of Action

12.1.2.3 Clinical Trial Results

12.1.2.4 Safety and Efficacy

12.1.2.5 Regulatory Status

12.1.3 URG101 - Urogen Pharmaceuticals

12.1.3.1 Drug Overview

12.1.3.2 Mechanism of Action

12.1.3.3 Clinical Trial Results

12.1.3.4 Safety and Efficacy

12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. INTERSTITIAL CYSTITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. INTERSTITIAL CYSTITIS – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 INTERSTITIAL CYSTITIS - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

- 15.2.1 Interstitial Cystitis - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Interstitial Cystitis - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Interstitial Cystitis - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Interstitial Cystitis - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Interstitial Cystitis - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Interstitial Cystitis - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Interstitial Cystitis - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Interstitial Cystitis - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Interstitial Cystitis - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Interstitial Cystitis - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Interstitial Cystitis - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Interstitial Cystitis - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Interstitial Cystitis - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Interstitial Cystitis - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy

- 15.7.1 Interstitial Cystitis - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
- 15.7.2 Interstitial Cystitis - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Interstitial Cystitis - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Interstitial Cystitis - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Interstitial Cystitis - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Interstitial Cystitis - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Interstitial Cystitis - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Interstitial Cystitis - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Interstitial Cystitis - Access and Reimbursement Overview

16 INTERSTITIAL CYSTITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 INTERSTITIAL CYSTITIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 INTERSTITIAL CYSTITIS MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Interstitial Cystitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/l8AA8E8EEDFBEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l8AA8E8EEDFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

